Body Vision Medical announces three strategic distribution agreements for Hong Kong, Macao and the entire Greater Bay Area (GBA), Australia and New Zealand, and Romania
The AI-powered LungVision System transforms X-ray images obtained from any C-arm device into real-time intraoperative CT scans. (Credit: Robina Weermeijer on Unsplash)
Body Vision Medical, a leader in AI-driven intraoperative imaging has signed exclusive distribution agreements with Prism Technologies Limited, Paragon Care and Kral Medical Solutions. These strategic partnerships facilitate Body Vision’s aim to introduce its cutting-edge LungVision real-time, intraoperative CT imaging system to the key markets of Hong Kong, Macao and the entire Greater Bay Area (GBA), Australia and New Zealand, and Romania, respectively.
The artificial intelligence (AI)-powered LungVision System transforms X-ray images obtained from any C-arm device into real-time intraoperative CT scans. This groundbreaking technology empowers bronchoscopists to visualize pulmonary lesions in real-time and ensuring precise biopsy during diagnostic bronchoscopy. By enhancing the precision and accuracy of the lung nodule biopsy procedure through real-time image-guidance, LungVision has the potential to enable an earlier cancer diagnosis and, thus, improved the long-term survival prospects of lung cancer patients.
David Webster, CEO of Body Vision Medical, expresses the significance of these exclusive distribution agreements, stating, “We view these partnerships as a pivotal stride towards democratizing Body Vision’s LungVision and giving lung patients worldwide access to the latest in AI-powered imaging technology. In many parts of the world with high lung cancer incidence, limited access to advanced medical solutions has translated into lower patient survival rates. With innovative yet cost-effective solutions like LungVision, we hope to challenge and change that status quo.”
In line with its growth strategy, Body Vision Medical aims to expand lung patient access to LungVision in 60 new markets within the next three years. With these strategic alliances in place, the company is poised to advance its mission of transforming lung cancer diagnosis and, potentially in the future, minimally-invasive, localized therapy delivery on a global scale.
Source: Company Press Release